Literature DB >> 16146671

Possible participation of advanced glycation end products in the pathogenesis of osteoporosis in diabetic patients.

S Yamagishi1, K Nakamura, H Inoue.   

Abstract

Osteoporosis, one of the most prevalent metabolic bone diseases in developed countries, is a major public health problem through its association with fragility fractures. Several epidemiological studies have reported moderately increased risks of osteoporotic bone fractures in diabetic patients compared with general population. However, the underlying molecular link between diabetes and osteoporosis remains to be elucidated. In diabetes mellitus, the formation and accumulation of advanced glycation end products (AGEs) progress. There is a growing body of evidence to show that AGEs-their receptor (RAGE) interactions are involved in the development of atherosclerosis and diabetic microangiopathy. AGEs enhance osteoclast-induced bone resorption in cultured mouse unfractionated bone cells. Furthermore, we have recently found that AGEs-RAGE interactions induced human mesenchymal stem cell apoptosis and subsequently prevented cognate differentiation into adipose tissue, cartilage, and bone. In vivo, serum levels of AGEs are elevated in patients with osteoporosis as well. These observations let us to hypothesize that AGEs could explain the molecular link between diabetes and osteoporosis. In this paper, we would like to propose the possible ways of testing our hypotheses. Does treatment with metformin, which has a potential effect on the inhibition of glycation reactions in vivo, decrease the risk for osteoporotic bone fractures in diabetic patients? If the answer is yes, is this beneficial effect of metformin superior to that of other anti-diabetic agents with equihypoglycemic properties? Does treatment with pyridoxamine, a post-Amadori inhibitor (so-called Amadorins) of AGE formation, reduce the risk for osteoporotic bone fractures as well? Furthermore, are increased levels of AGEs and RAGE in bone tissues associated with high risk for bone fractures in patients with diabetes? These clinical studies could clarify whether the AGEs-RAGE interactions serve as a causal link between diabetes and osteoporosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16146671     DOI: 10.1016/j.mehy.2005.07.017

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  33 in total

1.  Advanced Glycation End Products Affect Osteoblast Proliferation and Function by Modulating Autophagy Via the Receptor of Advanced Glycation End Products/Raf Protein/Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase Kinase/Extracellular Signal-regulated Kinase (RAGE/Raf/MEK/ERK) Pathway.

Authors:  Hong-Zheng Meng; Wei-Lin Zhang; Fei Liu; Mao-Wei Yang
Journal:  J Biol Chem       Date:  2015-10-15       Impact factor: 5.157

2.  The effects of diabetes medications on post-operative long bone fracture healing.

Authors:  C Simpson; D Jayaramaraju; D Agraharam; S Gudipati; R Shanmuganathan; P V Giannoudis
Journal:  Eur J Orthop Surg Traumatol       Date:  2015-08-29

Review 3.  [Particular features of steroid-induced osteoporosis].

Authors:  G E Hein
Journal:  Orthopade       Date:  2007-08       Impact factor: 1.087

Review 4.  Diabetes and bone health: latest evidence and clinical implications.

Authors:  Vikram Sundararaghavan; Matthew M Mazur; Brad Evans; Jiayong Liu; Nabil A Ebraheim
Journal:  Ther Adv Musculoskelet Dis       Date:  2017-01-24       Impact factor: 5.346

5.  Selenium inhibits high glucose-induced cyclooxygenase-2 and P-selectin expression in vascular endothelial cells.

Authors:  Yan-Bo Li; Jun-Yong Han; Wei Jiang; Jing Wang
Journal:  Mol Biol Rep       Date:  2010-11-05       Impact factor: 2.316

Review 6.  Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes--a meta-analysis.

Authors:  P Vestergaard
Journal:  Osteoporos Int       Date:  2006-10-27       Impact factor: 4.507

7.  Advanced glycation end products stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathways.

Authors:  Mani Alikhani; Zoubin Alikhani; Coy Boyd; Christine M MacLellan; Markos Raptis; Rongkun Liu; Nicole Pischon; Philip C Trackman; Louis Gerstenfeld; Dana T Graves
Journal:  Bone       Date:  2006-10-24       Impact factor: 4.398

8.  Positive association between serum uric acid and bone mineral density in Chinese type 2 diabetes mellitus stratified by gender and BMI.

Authors:  Mingxin Xu; Junlei Su; Jie Hao; Ni Zhong; Zhiyin Zhang; Ran Cui; Feng Li; Chunjun Sheng; Ge Zhang; Hui Sheng; Shen Qu
Journal:  J Bone Miner Metab       Date:  2017-11-09       Impact factor: 2.626

9.  Spinal deformity index in patients with type 2 diabetes.

Authors:  C Di Somma; M Rubino; A Faggiano; L Vuolo; P Contaldi; N Tafuri; N Tafuto; M Andretti; S Savastano; A Colao
Journal:  Endocrine       Date:  2012-12-11       Impact factor: 3.633

10.  Bone mineral density in prediabetic men.

Authors:  Ju Hee Lee; Yun Hyeong Lee; Kyoung Hye Jung; Min Kyeong Kim; Hye Won Jang; Tae Kyun Kim; Hyun Jin Kim; Young Suk Jo; Minho Shong; Tae Yong Lee; Bon Jeong Ku
Journal:  Korean Diabetes J       Date:  2010-10-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.